T Cell Lymphomas
Conference Coverage
VIDEO: How to prepare PTCL patients for transplant
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
News
FDA updates breast implant–associated lymphoma cases, risk
Estimates on the lifetime risk vary widely.
CME
The Long and Winding Road: PTCL 10 Years from Now
Conference Coverage
Best options for treating relapsed/refractory PTCL
LA JOLLA, CALIF. – Hematologists from the Royal Marsden Hospital in London review their best practices for the hardest to treat PTCL cases.
Conference Coverage
Mycosis fungoides increases risk for second cancers
LA JOLLA, CALIF. – The study mines data from the SEER-18 database.
Conference Coverage
Basiliximab/BEAM may improve post-ASCT outcomes in PTCL
LA JOLLA, CALIF. – The phase 1 trial is testing the use of a CD25 monoclonal antibody for achieving long-term remission in PTCL.
Conference Coverage
A view from the bridge to transplant for PTCL
LA JOLLA, CALIF. – Subtype and timing matter when considering the best bridge to transplant.
Conference Coverage
Getting hematologic cancer drugs on the fast track
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
Conference Coverage
T-cell lymphoma therapies on the horizon
LA JOLLA, CALIF. – Three new agents are in the pipeline for T-cell lymphoma.
Conference Coverage
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
ATLANTA – Mogamulizumab topped vorinostat in terms of overall response to treatment and on several quality of life scales
News
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphoma
Approval was based on a 56% objective response rate for brentuximab vedotin vs. 12% for physician’s choice of methotrexate or bexarotene in a...